IP Library Granted Patent US 8,846,715
Granted Patent B2
US 8,846,715 · App. 13/947,157 · Granted Sep 30, 2014

(2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof

Inventors: Merouane Bencherif (Winston-Salem, NC); Lisa Benson (Kernersville, NC); Gary Maurice Dull (Lewisville, NC); Nikolai Federov (Winston-Salem, NC); Gregory J. Gatto (Winston-Salem, NC); Kristen G. Jordan (Clemmons, NC); Anatoly A. Mazurov (Greensboro, NC); Lan Miao (Advance, NC); Julio A. Munoz (Walnut Cove, NC); Inigo Pfeiffer (Kernersville, NC); Sondra Pfeiffer (Kernersville, NC); Teresa Phillips (Greensboro, NC)
Assignee: Targacept, Inc.
C07D453/02A61K31/439A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,715
App. No.
13/947,157
Granted
Sep 30, 2014
Kind
B2
Abstract

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Claims (3)

1. A method for treating one or more of mild cognitive impairment, age-associated memory impairment, pre-senile dementia, early onset Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, or Alzheimer's disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, substantially free of (2S,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, (2R,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, (2R,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the treatment is for Alzheimer's disease.

3. The method of claim 1 , wherein the treatment is for early onset Alzheimer's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2016
From: CATALYST BIOSCIENCES, INC.
To: ATTENUA, INC.
Reel/Frame 039688/0771 →
CHANGE OF NAME Recorded Aug 11, 2016
From: TARGACEPT , INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 039646/0595 →
Continuity (7)
Continuation 13116080 · May 26, 2011
Continuation 12184312 · Aug 1, 2008
Provisional Application 60971654 · Sep 12, 2007
Provisional Application 60953610 · Aug 2, 2007
Provisional Application 60953613 · Aug 2, 2007
Provisional Application 60953614 · Aug 2, 2007
Related Publication 20140024673A1 · Jan 23, 2014